Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
. @Merck buys start-up Modifi Bio in a $1.3bn deal, getting rights to a new class of DNA repair drugs for difficult-to-treat cancers, including #glioblastoma. #oncology https://t.co/bTdwQflE1V
Modifi Biosciences, which develops therapies that stop cancer cells from making DNA, announced that it has been acquired by global pharmaceutical giant Merck, with a $30 million down payment. https://t.co/luu0nuRM3B
$XBI We got our big buyout, everyone. $MRK to buy privately held preclinical Modifi for $30mm upfront: https://t.co/xNiw89EtSz https://t.co/UyqfxaRBgA
Merck & Co. has acquired Modifi Biosciences, a Yale spinout focused on developing therapies for difficult-to-treat cancers, in a deal valued at up to $1.3 billion. The agreement includes an upfront payment of $30 million. Modifi's innovative approach targets cancer cells' ability to replicate DNA, with potential applications in treating conditions such as glioblastoma. This acquisition aligns with Merck's strategy to expand its oncology portfolio and enhance its capabilities in cancer treatment.
